Autoimmune Disease Therapeutics : Market Research Report

Autoimmune Disease Therapeutics

Published by: Global Industry Analysts

Published: Jul. 1, 2009 - 723 Pages

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS: Study Reliability and Reporting Limitations; Disclaimers; Quantitative Techniques & Analytics; Multiple Sclerosis
II. EXECUTIVE SUMMARY: 1.INDUSTRY OVERVIEW & OUTLOOK; Biotech Bankruptcies Rife in the Current EconomicDownturn; Analysis by Segment; 2.MARKET DYNAMICS AND TRENDS; New Indications to Fuel Market Growth; 3.DISEASE OVERVIEW; Table 1: Percentage Breakdown of Incidence ofAutoimmune Diseases in Men and Women(includes corresponding Graph/Chart); Etiology of Autoimmune Diseases; Environmental Factors; Types of Autoimmune Diseases; Incidence and Prevalence; Humira; Cimzia; Psoriasis - A Promising Market for Cimzia; 4.OVERVIEW OF SELECT AUTOIMMUNEDISEASES; Diagnosis; Drugs Used in Treating Rheumatoid Arthritis; Year of Approval of Leading Biologics in RheumatoidArthritis Therapy; Table 3: Comparative Analysis of Leading Biologic Rheumatoid Arthritis Drugs based on ACR Scoresby End Point; Multiple Sclerosis; Table 4: Prevalence of Different Types ofMultiple Sclerosis; Prevalence of Multiple Sclerosis High in Women; Interferon Drugs - High Efficacy Drugs in ExistingMS Therapies; Non-Interferon Drugs in Multiple SclerosisTreatment; Oral Drugs in Pipeline to Alter Market Dynamics inMS Therapies; Dip in Sales Inevitable for Current Therapies; Competitive Landscape; Table 5: Leading Multiple Sclerosis Drugs Worldwide(2007) by Sales: Avonex, Rebif, Copaxone, Betaseronand Tysabri (includes corresponding Graph/Chart); Multiple Sclerosis Drug Pipeline - An Overview; Laquinimod; Teriflunomide; Psoriasis; Biological Drugs Lead the Fray; Inflammatory Bowel Diseases; Treatment; Global Crohn’s Disease Therapeutics Market:Leading Biological Drugs and their Worldwide; Other Diseases; Sjogren's Syndrome; Prevalence and Epidemiology; Types of Diabetes Mellitus; Prevalence; Autoimmune Hepatitis; Juvenile Rheumatoid Arthritis; Prevalence; Haematologic Autoimmune Diseases; 5.PRODUCT INTRODUCTIONS/APPROVALS; Cimzia® Receives FDA Nod for Treating Crohn’s Disease; Xian-Janssen Introduces Remicade, Branded infliximabin China; Tysabri™ Receives Health Canada Approval for Usein Multiple Sclerosis; Betaseron® Receives FDA Approval for Use in FirstClinical Episode of MS; 6.RECENT INDUSTRY ACTIVITY; Apitope Raises Financing for Developing MultipleSclerosis Compound; Roche Acquires ARIUS Research, Inc.; Carna and Caliper Life Sciences Ink Collaborative SupplyAgreement; Boehringer In-licenses Two Drug Targets from BioFocus; Nycomed Inks Agreement with Immunomedics forVeltuzumab; Boehringer to Takeover Actimis; Merrimack Acquires Funds for Developing Cancer andAutoimmune Disease Biologics; ANP Completes Phase IIa Trial for Multiple Sclerosis Drug; Debiopharm Inks licensing Deal with Airmid forDebio 0824 ShK Peptide; Cypress Bioscience Acquires Proprius; Hadasit, HMS and BWH to Co-develop Oral Therapyfor Autoimmune Diseases; Cambridge Inks an Antibody Development Agreementwith Medarex; Amgen Acquires Avidia; Eli Lilly and MacroGenics Tie Up for DevelopingTeplizumab; arGentis Enters into a License Agreement with UTRF; Organon and Dyax Team Up for DevelopingTherapeutic Antibodies; Genzyme Takes Over Bioenvision; Xanthus Secures Exclusive Patent Estate Rights forFLT3 Pathway; TIRC Changes Name to Orchestra Therapeutics; Medarex and Compugen Ink Collaborative Agreementfor Therapeutic Antibody; SRI and Telik Sign License Agreement for Drug Development; Kirin and Astellas Ink Licensing Agreement forAnti-CD40 Antagonistic mAb; JDRF and MacroGenics Form Partnership; Biocon Enters into Joint Venture Agreement withNeopharma; Astellas Acquires Worldwide Rights for Amevive®; 7.FOCUS ON SELECT GLOBAL PLAYERS; Bayer Schering Pharma AG (Germany); Biogen Idec Inc. (USA); Bristol-Myers Squibb Company (USA); Elan Corporation, plc (Ireland); Eli Lilly And Company (USA); Chugai Pharmaceutical Co., Ltd. (Japan); Genentech, Inc. (USA); GlaxoSmithKline plc (UK); Johnson & Johnson, Inc. (USA); Merck Serono SA (Switzerland); Sanofi-aventis SA (France); Schering-Plough Corporation (USA); Teva Pharmaceuticals Industries Limited (Israel); UCB Pharma (Belgium); 8.GLOBAL MARKET PERSPECTIVE; Table 9: World 10-year Perspective for AutoimmuneDisease Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe andRest of World Markets for Years 2006, 2009 & 2015(includes corresponding Graph/Chart); Table 10: World Recent Past, Current & Future Analysisfor Rheumatoid Arthritis Therapeutics by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006through 2015 (includes corresponding Graph/Chart); Table 11: World 10-year Perspective for RheumatoidArthritis Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe andRest of World Markets for Years 2006, 2009 & 2015(includes corresponding Graph/Chart); Table 12: World Recent Past, Current & Future Analysisfor Multiple Sclerosis Therapeutics by Geographic Region -US, Japan, Europe and Rest of World- MarketsIndependently Analyzed with Annual Sales in US$Billion for Years 2006 through 2015 (includescorresponding Graph/Chart); Table 13: World 10-year Perspective for MultipleSclerosis Therapeutics by Geographic Region -Percentage Breakdown of Dollar Sales for US, Japan,Europe and Rest of World Markets for Years 2006, 2009 &2015 (includes corresponding Graph/Chart); Table 14: World Recent Past, Current & Future Analysis for Psoriasis Therapeutics by Geographic Region - US, Japan, Europe and Rest of World- Markets Independently Analyzedwith Annual Sales in US$ Billion for Years 2006through 2015 (includes corresponding Graph/Chart); Table 15: World 10-year Perspective for PsoriasisTherapeutics by Geographic Region - Percentage Breakdownof Dollar Sales for US, Japan, Europe and Rest of WorldMarkets for Years 2006, 2009 & 2015 (includescorresponding Graph/Chart); Table 16: World Recent Past, Current & Future Analysis for Crohn’s Disease Therapeutics (Biologics) by Geographic Region - US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006through 2015 (includes corresponding Graph/Chart); Table 17: World 10-year Perspective for Crohn’s Disease Therapeutics (Biologics) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe andRest of World Markets for Years 2006, 2009 & 2015(includes corresponding Graph/Chart); Table 18: World Recent Past, Current & Future Analysis for Other Autoimmune Disease Therapeutics by GeographicRegion - US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales in US$Billion for Years 2006 through 2015 (includescorresponding Graph/Chart); Table 19: World 10-year Perspective for Other Autoimmune Disease Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europeand Rest of World Markets for Years 2006, 2009 & 2015(includes corresponding Graph/Chart)
III. MARKET: 1.THE UNITED STATES; Table 20: Prevalence of Key AutoimmuneDiseases in the US for 2006 (in Millions)(includes corresponding Graph/Chart); Rheumatoid Arthritis Drugs Lead the Market; Table 21: US Multiple Sclerosis Drug Market (2006): Percentage Breakdown of Number of Dispensed Prescriptions for Avonex, Copaxone, Rebif,Betaseron and Tysabri (includes corresponding Graph/Chart); Key Ulcerative Colitis Drugs Market in theUS (2006); Product Launches/ Approvals; Strategic Corporate Developments; Key Players; B. Market Analytics; Table 24: US 10-year Perspective forAutoimmune Disease Therapeutics by DiseaseSegment - Percentage Breakdown of DollarSales for Rheumatoid Arthritis, Multiple Sclerosis,Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2006, 2009 & 2015(includes corresponding Graph/Chart); 2.JAPAN; B. Market Analytics; Table 26: Japanese 10-year Perspective for Autoimmune Disease Therapeutics by Disease Segment - Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis,Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics)and Other Autoimmune Diseases for Years 2006, 2009 &2015 (includes corresponding Graph/Chart); 3.EUROPE; Table 27: Prevalence of Key AutoimmuneDiseases in Europe for 2006 in Millions(includes corresponding Graph/Chart); Product Launches/Approvals; Strategic Corporate Developments; Key Players; B. Market Analytics; Table 29: European 10-year Perspective forAutoimmune Disease Therapeutics byDisease Segment - Percentage Breakdown ofDollar Sales for Rheumatoid Arthritis, MultipleSclerosis, Psoriasis, Crohn’s Disease (Biologics) andOther Autoimmune Diseases for Years 2006, 2009 &2015 (includes corresponding Graph/Chart); 4.REST OF WORLD; Asia-Pacific; Overview of Rheumatoid Arthritis in Australia; Table 31: Percentage Breakdown ofPrevalence of Rheumatoid Arthritis inAustralia by Sex (includes corresponding Graph/Chart); Product Launches/Approvals; Strategic Corporate Developments; B. Market Analytics; Table 33: Rest of World 10-year Perspective forAutoimmune Disease Therapeutics by DiseaseSegment - Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis,Crohn’s Disease (Biologics) and Other AutoimmuneDiseases for Years 2006, 2009 & 2015 (includescorresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE: Total Companies Profiled: 115 (including Divisions/Subsidiaries - 122); Region/Country Players; The United States; Canada; Japan; Europe; Asia-Pacific (Excluding Japan)

Abstract

This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Billion by the following therapeutic class - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics only), and Others. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. The report profiles 115 companies including many key and niche players worldwide such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co., Ltd., Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck Serono SA, Novartis AG, Sanofi-aventis SA , Schering-Plough Corporation, Shire Pharmaceuticals Group plc, Teva Pharmaceuticals Industries Limited, and UCB Pharma. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Titles available via "online download" are not affected by this and are still delivered to your reading room immediately.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Autoimmune Disease Therapeutics

Table of Contents

Abstract